Si-Yu Chen

Ms. Si-Yu Chen

orcid

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

31 July 2023 in Sensors and Actuators B: Chemical
Verified
Journal Article
Closed access
XZXia Zhou
Xia Zhou
HHHaiqiu Huang
Haiqiu Huang
YYYingqi Yang
Yingqi Yang
HZHanlin Zhou
Hanlin Zhou
RLRuiyu Liang
Ruiyu Liang
HZHaibo Zhou
Haibo Zhou

24 July 2025 in Environmental Pollution
Verified
Journal Article
Closed access
SCSi-Yu Chen
Si-Yu Chen
CHCheng-Chieh Hsieh
Cheng-Chieh Hsieh
CLChung-Min Liao
Chung-Min Liao
Szu-Chieh ChenSzu-Chieh Chen
Szu-Chieh Chen

5 September 2025 in Viruses
Verified
Journal Article
Open access
PDF file
Yang YangYang Yang
Yang Yang
Min-Pei LingMin-Pei Ling
Min-Pei Ling
Szu-Chieh ChenSzu-Chieh Chen
Szu-Chieh Chen
YLYi-Jun Lin
Yi-Jun Lin
SYshuhan you
shuhan you
CLChung-Min Liao
Chung-Min Liao
Long COVID, characterized by persistent symptoms following acute SARS-CoV-2 infection, has emerged as a significant public health challenge with wide-ranging clinical and socioeconomic implications. Developing an effective risk assessment strategy is essential for the early identification and management of individuals susceptible to prolonged symptoms. This study uses a quantitative approach to characterize the dose–response relationships between spike protein concentrations and effects, including Long COVID symptom numbers and the release of proinflammatory mediators. A mathematical model is also developed to describe the time-dependent change in spike protein concentrations post diagnosis in twelve Long COVID patients with a cluster analysis. Based on the spike protein concentration–Long COVID symptom numbers relationship, we estimated a maximum symptom number (~20) that can be used to reflect a persistent predictor. We found that among the crucial biomarkers associated with Long COVID proinflammatory mediator, CXCL8 has the lowest 50% effective dose (0.01 μg mL−1), followed by IL-6 (0.39), IL-1β (0.46), and TNF-α (0.56). This work provides a comprehensive risk assessment strategy with dose–response tools and mathematical modeling developed to estimate potential spike protein concentration. Our study suggests persistent Long COVID guidelines for personalized care strategies and could inform public health policies to support early interventions that reduce long-term disability and healthcare burdens with possible other post-infection syndromes.

6 January 2025 in Heliyon
Verified
Journal Article
Open access
CLChun-Hui Lin
Chun-Hui Lin
CHCheng-Chieh Hsieh
Cheng-Chieh Hsieh
SCSi-Yu Chen
Si-Yu Chen
HCHong-Ru Chen
Hong-Ru Chen
Szu-Chieh ChenSzu-Chieh Chen
Szu-Chieh Chen
This study used the Disability-Adjusted Life Years (DALYs) to quantify the long-term trends for four cancers (oral cancer, colorectal cancer, breast cancer, and cervical cancer) that have undergone cancer screening in Taiwan. DALYs were calculated as the sum of Years of Life Lost (YLL) due to premature mortality and Years Lived with Disability (YLD). YLLs were determined using cancer-specific mortality data from the Health Promotion Administration (HPA), Ministry of Health and Welfare, based on age-specific life expectancy. YLDs were estimated by combining the incidence rates of the cancers, average disability durations, and disability weights, with data sourced from the Taiwan Cancer Registry. Results were expressed as DALYs per 100,000 population. The disease burden has significantly increased over the past 12 years. Oral cancer rose from 263 to 368 DALYs per 100,000 population (40 % increase), colorectal cancer from 343 to 563 DALYs (64 % increase), and breast cancer from 446 to 782 DALYs (75 % increase), while the burden of cervical cancer decreased from 168 to 147 DALYs per 100,000 population from 2010 to 2017, showing a 13 % reduction. At the cancer stages, the impact of YLDs was mostly at cancer stage IV (oral cancer), cancer stage 0 (colorectal and cervical cancer), and stage I (breast cancer). Oral cancer increased by 40 %, colorectal cancer by 64 %, and breast cancer by 75 % from 2005 to 2017, while cervical cancer decreased by 13 % between 2010 and 2017. YLD contributions were highest in stage IV for oral cancer, stage 0 for colorectal and cervical cancers, and stage I for breast cancer. The highest DALYs consistently occurred in the 50–69 age group across all cancer types, highlighting the significant burden on middle-aged populations.

23 July 2025 in Preprints.org
Verified
Preprint
Open access
PDF file
Yang YangYang Yang
Yang Yang
Min-Pei LingMin-Pei Ling
Min-Pei Ling
Szu-Chieh ChenSzu-Chieh Chen
Szu-Chieh Chen
YLYi-Jun Lin
Yi-Jun Lin
SYshuhan you
shuhan you
CLChung-Min Liao
Chung-Min Liao
Long COVID, characterized by persistent symptoms following acute SARS-CoV-2 infection, has emerged as a significant public health challenge with wide-ranging clinical and socioeconomic implications. Developing an effective risk assessment strategy is essential for early identification and management of individuals susceptible to prolonged symptoms. This study uses a quantitative approach to characterize the dose-response relationships between spike protein concentrations and effects including Long COVID symptom numbers and release of proinflammatory mediators. A mathematical model is also developed to describe the time-dependent change of spike protein concentrations post diagnosis in twelve Long COVID patients with a cluster analysis. Based on the spike protein concentrationLong COVID symptom numbers relationship, we estimated a maximum symptom number (~20) that can be used to reflect a persistent predictor. We found that among the crucial biomarkers associated with Long COVID proinflammatory mediator, CXCL8 has the lowest 50% effective dose (0.01 μg mL-1), followed by IL-6 (0.39), IL-1β (0.46), and TNF-α (0.56). This work provides a comprehensive risk assessment strategy with developed dose-response tools and mathematical modeling to estimate potential spike protein concentration. Our study implicates a persistent Long COVID guideline for personalized care strategies and informs public health policies to support early interventions that reduce long-term disability and healthcare burdens with possibly other postinfection syndromes.